By Fineline Cube 
China-based HighTide Therapeutics, Inc. (HKG: 2511) announced the commencement of a collaborative project with the Institute of Medicinal Biotechnology (IMB), Chinese Academy of Medical Sciences. The partnership focuses on evaluating the therapeutic potential of HighTide’s core product, HTD1801, for the treatment of type 2 diabetes mellitus with chronic kidney disease (CKD with T2DM).
HTD1801 Mechanism
HTD1801, HighTide’s lead drug candidate, is a first-in-class orally delivered, gut-liver anti-inflammatory metabolic modulator. It uniquely activates AMPK and inhibits the NLRP3 inflammasome, offering a dual mechanism of action. This collaboration combines IMB’s resources in drug research and medical science with HighTide’s expertise in metabolic disease product development to accelerate clinical advancements and enhance therapeutic applications.
Collaboration Goals
The collaboration aims to leverage IMB’s resource advantages and HighTide’s core competencies to develop innovative therapeutics for glyco-renal metabolic-related diseases. Joint mechanism research and clinical development efforts will expand the clinical applications of HTD1801 in treating CKD with T2DM.-Fineline Info & Tech